eng- facts about buprenorphine samhsa

8/17/2019 Eng- Facts About Buprenorphine SAMHSA

1/16

!

!"# %&'!( &)*+!

,-./012/.3410

"#$ &$'()*'+) #",-!#!. /..!0)!#+


2/16

!!

123. 4''+ 56#) #+ )6' 5)$'')57 23. 4''+ !+

.')#89 2) :(5 ;(!

!"# %" &"' ()*+,( -."/ 01( /2)(.& +3% .2)4) "- %.'5

+%%2*02"36 7")0 ,(",8( *+33"0 %" 20 "3 01(2. "#39 :1(& 3((%1(8, 0" .(0'.3 0" 3"./+8; 1(+801& 82+))2)0(% 0.(+0/(309

:1(.( +.( 01.((; (?'+88& 2/,".0+30 ,+.0) 0" 012) -"./ "-

0.(+0/(30@

! 7(%2*+02"3

! A"'3)(8235

! B',,".0 -."/ -+/28& +3% -.2(3%)9#$%&'()&%*+(' 2) "3( 0&,( "- /(%2*+02"3 ')(% -". 0.(+0/(30

"- ",2"2% +%%2*02"39 C(.1+,) &"'. %"*0". ". )'D)0+3*( +D')(

0.(+0/(30 ,."


3/16

BB

,-!#!. (..!0)!#+ !5 ( .!5'(5'9=,2"2%) +.( %.'5) 01+0 )8"# %"#3 01( +*02"3) "- 01( D"%&; )'*1 +)D.(+01235 +3% 1(+.0D(+09 =,2"2%) +8)" +--(*0 01( D.+23 0" 23*.(+)(

,8(+)+30 -((8235)9 :1(& 5(0 01(2. 3+/( -."/ ",2'/; + %.'5 /+%(

-."/ 01( ,",,& ,8+309

=,2"2% /(%2*+02"3) +.( ,.()*.2D(% 0" 0.(+0 ,+23 +3% )"/(02/()

-". "01(. 1(+801 ,."D8(/) )'*1 +) )(


4/16

G

E"0 (-())2"3+8) +3% )'D)0+3*( +D')( 0.(+0/(30 ,."


5/16

H

G- &"' +.( +%%2*0(%; /(%2*+02"3 +88"#) &"' 0" .(5+23 + 3"./+8

)0+0( "- /23%; -.(( "- %.'5>23%'*(% 1251) +3% 8"#)9 G0 -.(() &"'

-."/ 01234235 +88 01( 02/( +D"'0 01( %.'59 G0 *+3 .(%'*( ,."D>8(/) "- #201%.+#+8 +3% *.+

02"3 %"() E=: *.(+0( + 3(# +%%2*02"39 G0 1(8,) &"' /+3+5( &"'.

+%%2*02"3 )" 01+0 01( D(3(-20) "- .(*"

H')0 &"'. /(%2*+02"3 ". 1(8, &"' -23% "01(. #+&) 0" .(%'*( 01(/9


6/16

II

R"' 0+4( D',.(3".,123( +) + ,288 01+0 %2))"8


7/16

CC

+D')235 %.'5)9 R"'. 82.2)4 0+)4) '3028 &"' 43"# 1"# 012)

/(%2*+02"3 +--(*0) &"'9 G- %."#)23()) *"3023'() 0" D( + ,."D8(/;

&"'. %"*0". /+& +%H')0 %")( 8(


8/16


9/16

L

5I==IG @BJK KLLK5;@

EGJ @B=M8K DEN@ ;I FKJO5K ;PK=

#).0 24*'9Q *'2.24*'9Q 2(. 4)-.> )& :-$>-+R' 90


10/16

MM

N#=+5'

",,".0'320& 0" 0+84 #201 + ,."-())2"3+8 (201(. "3(>"3>"3( ".

23 + 5."', #201 "01(.) 23 0.(+0/(309

:1."'51 *"'3)(8235; &"' 8(+.3 +D"'0 01( /"02


11/16

OO

P(*!


12/16

;

* '

L 2 4 / 9

EJJB5;BIG DPE;T@ ;FOK EGJ DPE;T@ GI;

E..+4/+)( +9 2 .+9'29'1 G0 *+33"0 D( *'.(%; D'0 20 *+3

D( 0.(+0(% #201 /(%2*+02"3; *"'3)(8235; +3% )',,".0

-."/ -+/28& +3% -.2(3%)9 O%%2*02"3 2) E=: + )253 "-

#(+43())9 G0 2) E=: :XMF 01+0 +88 &"' 3((% 0" 42*4

+%%2*02"3 2) 0" ID( )0."359J

;*' 7)2- ):


13/16

BB

;

* ' L 2 4 / 9

#OMFKGIFMPBGK DPE;T@ ;FOK EGJ DPE;T@ GI;

#$%&'()&%*+(' *'-%9 0)$ /*+(R 2(. :$(4/+)(

()&

/+)(9 2(. 9)-. -'72--01 :1(.( 2) 3" .2)4 "- 5(00235

0+230(% %")(); #12*1 *+3 1+,,(3 #201 )0.((0 %.'5)9

O8)"; .2)4 "- "


14/16

BGBG

S=--#$) J$#=-5 (+. !+"#$*()!#+

! :12) 2) 3"0 + *"/,8(0( 82)09 V2)0235 1(.( %"() 3"0 /(+3 01+0 01( B'D)0+3*( OD')( +3% 7(30+8 !(+801 B(.

02"3 ZBO7!BO\ (3%".)() +3& "- 01( ".5+32U+02"3)9

! B"/( )',,".0 5."',) 1+"38& ,"82*2() +3% %"

3"0 8""4 -+D+)(% )',,".0 5."', /+& D( &"'. D()0 ",02"3

2- 3" 5."',) /((0 23 &"'. *"//'320&9 O3"01(. ",02"3 2) 0"

*"30+*0 O8*"1"82*) O3"3&/"') ZOO; 100,@^^###9++9".5\ 0"

-23% "'0 #1(01(. OO /((0235) 23 &"'. *"//'320& +.( ",(3

0" ,(",8( 23 .(*"c[[>d[d]

G2/+)(2- E--+2(4' ): E.6)42/'9 :)& #$%&'()&%*+('

;&'2/


15/16

BH

@=EF; F'4)6'&0

100,@^^###9)/+.0.(*"_e[>e`ea

D)dca>dcc_ :KK Z-". 1(+.235 2/,+2.(%\

100,@^^D',.(3".,123(9)+/1)+95"BO7!BO>a Z[>caa>a]f>da]a\

ZF3582)1 +3% F),+g"8\9


16/16

1E6() 23A' "#=+. !+ *@

O%/232)0.+02"3 ZBO7!BO\ D& 01( i3"#8(%5( O,,82*+02"3 C."5.+/ ZiOC\; + Q"230 k(30'.(

"- :1( AK7 W."',; G3*9; +3% QPB G30(.3+02"3+8; G3*9; '3%(. *"30.+*0 3'/D(. ]ab>bd>

abd_; #201 BO7!BO; M9B9 K(,+.0/(30 "- !(+801 +3% !'/+3 B(.

eng- facts about buprenorphine samhsa

Documents